Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAM cocktail in critically ill patients with COVID-19 pneumonia
IRCT20200415047080N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of thiamine, ascorbic acid and methylprednisolone in coronavirus pneumonia (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Change in SF ratio, Time to mechanical ventilation weaning and 1 more. Started Apr 2020; status: completed.
02
Drugs
thiamineascorbic acidmethylprednisolone
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200415047080N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200415047080N2.